Results 171 to 180 of about 274,125 (232)

Enhancing quality of life: addressing vulvovaginal atrophy and urinary tract symptoms

Climacteric
About 50% of postmenopausal women experience symptoms of vulvovaginal atrophy (VVA) including vulvovaginal dryness, burning, itching and dyspareunia as a natural physiological consequence of hypoestrogenism.
Angelica Lindén Hirschberg
semanticscholar   +1 more source

New developments in the management of vulvovaginal atrophy: a comprehensive overview

Expert Opinion on Pharmacotherapy, 2023
Proper recognition and individualized therapy of vulvovaginal atrophy (VVA) is paramount.Assessment of VVA should be performed using several questionnaires in combination with wet mount microscopy to determine Vaginal Cell Maturation Index (VCMI) and infections.
Donders, Gilbert, Donders, Francesca H.W.V.   +1 more
openaire   +3 more sources

Hyaluronic acid injection to treat symptoms of vulvovaginal atrophy in postmenopausal women: A 12-week randomised, placebo-controlled, multicentric study.

Maturitas
OBJECTIVE To evaluate the efficacy and safety of a single injection session of cross-linked hyaluronic acid gel for vulvovaginal atrophy, versus placebo.
Fabienne Marchand Lamiraud, Hichem Bensmail, C. Martin, Sofie Pelckmans, Firas Cha'ban, Aliette Siboni Frisch, Gulcan Deniz, Pascale Sabban Serfati, Brigitte Caubo, Brice Gurriet, Isabelle Petit Breuilh, Ann Inge Pastijn, N. Berreni, Michel Cosson   +13 more
semanticscholar   +1 more source

Advances in the treatment of vulvovaginal atrophy

Expert Review of Obstetrics & Gynecology, 2013
Vulvovaginal atrophy is a frequently neglected symptom of menopause. While an estimated 10–40% of women are affected by the progressive symptoms of vaginal dryness, irritation, itching, dysuria and dyspareunia, only a quarter of symptomatic women are believed to seek medical attention. Until recently, treatments for vulvovaginal atrophy were limited to
Jill M Krapf, Zoe R Belkin, Andrew T Goldstein   +2 more
openaire   +1 more source

Current approaches to the treatment of vulvovaginal atrophy in women with gynecological and breast cancer

FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
Background. Treatment of vulvovaginal atrophy (VVA) in women diagnosed with gynecologic or breast cancer presents challenges. Treatment options for VVA, the genital manifestation of the genitourinary syndrome of menopause (GSM), generally mirror those ...
O. Gridasova, A. Solopova, E. I. Rumyantseva, A. Ivanov, D. Utkin, J. Khizroeva   +5 more
semanticscholar   +1 more source

The effectiveness of vitamin D as an alternative to FDA‐approved treatment and other therapies for managing vulvovaginal atrophy and sexual inactivity in postmenopausal women. A systematic review and meta‐analysis

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
Vulvovaginal atrophy (VVA) and sexual inactivity (SI) are prevalent among postmenopausal women (PMW). While hormonal therapies show significant improvement, non‐hormonal therapies are considered the first‐line for breast cancer women.
Eman Youssef, Mostafa Saad Badie, Doaa Ismail, Aliaa Gamal, H. Eldamanhoury   +4 more
semanticscholar   +1 more source

Injection Treatments for Vulvovaginal Atrophy of Menopause: A Systematic Review

Aesthetic Plastic Surgery, 2023
Injection treatments have been proposed as novel treatment options for Vulvovaginal Atrophy of Menopause (VVA) also known as Genitourinary Syndrome of Menopause (GSM). However, to date data about these treatments are poor.To assess all available injection treatments for VVA.A systematic review was performed by searching five electronic databases for ...
Moccia, Felice, Pentangelo, Paola, Ceccaroni, Alessandra, Raffone, Antonio, Losco, Luigi, Alfano, Carmine   +5 more
openaire   +4 more sources

Effect of a rehabilitation program on magnesium levels in women with vulvovaginal atrophy in surgical menopause

Journal of Medical Rehabilitation
Background. Magnesium deficiency (MD) is a prevalent issue among women after radical treatment for gynecological cancers, particularly in the context of surgical menopause.
A. Vorobev, A. B. Hajiyeva, E. A. Son
semanticscholar   +1 more source

Prasterone: A Review in Vulvovaginal Atrophy

Drugs & Aging, 2019
Vulvovaginal atrophy (VVA) is a progressive condition commonly seen in postmenopausal women. The cessation of ovarian estrogen secretion and a fall in serum levels of dehydroepiandrosterone (DHEA), the remaining source of estrogens and androgens, are thought to promote the development of VVA in this population. Intravaginal prasterone (Intrarosa®) is a
openaire   +2 more sources

Treatment of Dyspareunia Secondary to Vulvovaginal Atrophy

Nursing for Women's Health, 2014
Declining estrogen levels associated with menopause can result in vulvovaginal atrophy and some degree of dyspareunia for more than half of all women in menopause. In 2013, the U.S. Food and Drug Administration approved ospemifene, a nonhormonal oral medication for the treatment of dyspareunia in menopause.
openaire   +2 more sources